Interplay between H6PDH and 11β-HSD1 implicated in the pathogenesis of type 2 diabetes

被引:7
|
作者
Yao, Fan [1 ]
Chen, Li [1 ,2 ]
Fan, Zheng [1 ]
Teng, Fei [1 ]
Zhao, Yali [1 ]
Guan, Fengying [1 ]
Zhang, Ming [1 ]
Liu, Yanjun [3 ]
机构
[1] Jilin Univ, Dept Pharmacol, Coll Basic Med Sci, Changchun 130021, Peoples R China
[2] Jilin Univ, Sch Nursing, Changchun 130021, Peoples R China
[3] Univ Calif Los Angeles, Sch Med, Div Endocrinol Metab & Mol Med, Charles R Drew Univ Med & Sci, Los Angeles, CA USA
基金
中国国家自然科学基金;
关键词
H6PDH; 11; beta-HSD1; Corticosterone; Liver; Type 2 diabetes mellitus; 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE-1; HEXOSE-6-PHOSPHATE DEHYDROGENASE; GLUCOCORTICOID-RECEPTOR; INSULIN-RESISTANCE; DB/DB MICE; EXPRESSION; CONTRIBUTE; OBESITY; HYPERGLYCEMIA; HEPATOCYTES;
D O I
10.1016/j.bmcl.2017.07.043
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Extensive studies have been performed on the role of 11 beta-hydroxysteroid dehydrogenase 1 (11 beta-HSD1) in metabolic diseases. Our previous study reported glucose could directly regulate hexose-6-phosphate dehydrogenase (H6PDH) and 11 beta-HSD1. Recently, we further investigated the interplay of H6PDH and 11 beta-HSD1 and their roles in hepatic gluconeogenesis and insulin resistance to elucidate the importance of H6PDH and 11 beta-HSD1 in pathogenesis of type 2 diabetes mellitus (T2DM). T2DM rats model and H6PDH or 11 beta-HSD1 siRNA transfected in CBRH-7919 cells were used to explore the effect of H6PDH and 11 beta-HSD1 in T2DM. The results showed that the expression and activity of H6PDH and 11 beta-HSDI in livers of diabetic rats were increased, with the expressions of PEPCK and G6Pase or liver corticosterone increased apparently. It also showed that H6PDH siRNA and 11 beta-HSD1 siRNA could inhibit the protein expression and enzyme activity by each other. With H6PDH siRNA, the enhancement of gluconeogenesis was blocked and insulin resistance stimulated by corticosterone was reduced. H6PDH and 11 beta-HSD1 might be the effective and prospective targets for T2DM and metabolic syndromes, based on the interplay between these two enzymes. (C) 2017 Elsevier Ltd. All rights reserved.
引用
收藏
页码:4107 / 4113
页数:7
相关论文
共 34 条
  • [1] Biomarkers of hypothalamic-pituitary-adrenal axis activity in mice lacking 11β-HSD1 and H6PDH
    Abrahams, Lianne
    Semjonous, Nina M.
    Guest, Phil
    Zielinska, Agnieszka
    Hughes, Beverly
    Lavery, Gareth G.
    Stewart, Paul M.
    JOURNAL OF ENDOCRINOLOGY, 2012, 214 (03) : 367 - 372
  • [2] Development of 11β-HSD1 inhibitors for the treatment of type 2 diabetes
    Hale, Clarence
    Wang, Minghan
    MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2008, 8 (07) : 702 - 710
  • [3] G6PT-H6PDH-11βHSD1 triad in the liver and its implication in the pathomechanism of the metabolic syndrome
    Ibolya Czegle
    Miklós Csala
    József Mandl
    Angelo Benedetti
    István Karádi
    Gábor Bánhegyi
    World Journal of Hepatology, 2012, 4 (04) : 129 - 138
  • [4] G6PT-H6PDH-11 beta HSD1 triad in the liver and its implication in the pathomechanism of the metabolic syndrome
    Czegle, Ibolya
    Csala, Miklos
    Mandl, Jozsef
    Benedetti, Angelo
    Karadi, Istvan
    Banhegyi, Gabor
    WORLD JOURNAL OF HEPATOLOGY, 2012, 4 (04) : 129 - 138
  • [5] 11-Beta-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors in Type 2 diabetes mellitus and obesity
    Hughes, Katherine A.
    Webster, Scott P.
    Walker, Brian R.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2008, 17 (04) : 481 - 496
  • [6] Metformin Increases Cortisol Regeneration by 11βHSD1 in Obese Men With and Without Type 2 Diabetes Mellitus
    Anderson, Anna J.
    Andrew, Ruth
    Homer, Natalie Z.
    Jones, Gregory C.
    Smith, Kenneth
    Livingstone, Dawn E.
    Walker, Brian R.
    Stimson, Roland H.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2016, 101 (10) : 3787 - 3793
  • [7] Inhibition of 11β-HSD1 by LG13 improves glucose metabolism in type 2 diabetic mice
    Zhao, Leping
    Pan, Yong
    Peng, Kesong
    Wang, Zhe
    Li, Jieli
    Li, Dan
    Tong, Chao
    Wang, Yi
    Liang, Guang
    JOURNAL OF MOLECULAR ENDOCRINOLOGY, 2015, 55 (02) : 119 - 131
  • [8] Triterpene saponins from Barringtonia acutangula (L.) Gaertn as a potent inhibitor of 11β-HSD1 for type 2 diabetes mellitus, obesity, and metabolic syndrome
    Vishal Shivalingappa Patil
    Nayeem A. Khatib
    Clinical Phytoscience, 6 (1)
  • [9] Identification and optimisation of 3,3-dimethylazetidin-2-ones as potent and selective inhibitors of 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1)
    McCoull, William
    Augustin, Martin
    Blake, Caroline
    Ertan, Anne
    Kilgour, Elaine
    Krapp, Stephan
    Moore, Jane E.
    Newcombe, Nicholas J.
    Packer, Martin J.
    Rees, Amanda
    Revill, John
    Scott, James S.
    Selmi, Nidhal
    Gerhardt, Stefan
    Ogg, Derek J.
    Steinbacher, Stefan
    Whittamore, Paul R. O.
    MEDCHEMCOMM, 2014, 5 (01) : 57 - 63
  • [10] Synthesis and structure-activity relationship of 2-adamantylmethyl tetrazoles as potent and selective inhibitors of human 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1)
    Ye, Xiang-Yang
    Yoon, David
    Chen, Stephanie Y.
    Nayeem, Akbar
    Golla, Rajasree
    Seethala, Ramakrishna
    Wang, Mengmeng
    Harper, Timothy
    Sleczka, Bogdan G.
    Apedo, Atsu
    Li, Yi-Xin
    He, Bin
    Kirby, Mark
    Gordon, David A.
    Robl, Jeffrey A.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2014, 24 (02) : 654 - 660